If I recall correctly, we actually had a bit of a sell off during ASCO and the stock took off after ASCO thanks to some terrific releases from the company and subsequent upgrades from analysts.
I am wondering if we might see significant appreciation happen after phase 2 data is presented at ASH. We might all be underestimating this company.
News 
Market Data 
Discover 
